Home / Health / Cancer Drug Costs Cripple Patients Despite Price Caps
Cancer Drug Costs Cripple Patients Despite Price Caps
6 Nov
Summary
- Trade margins on 137 anti-cancer drugs capped at 30%.
- Karnataka flagged markups up to 52 times the procurement cost.
- Rising cancer burden in Karnataka shows a 10.2% increase.
Advances in cancer treatment are out of reach for many due to prohibitive costs, even with recent measures to cap trade margins on 137 non-scheduled anti-cancer medicines at 30%. This intervention, effective November 9, 2026, aims to save an estimated ₹2,500 crore annually, potentially reducing some drug prices by up to 70%.
However, oncologists caution that margin caps are only part of the solution. High manufacturer prices and treatment costs beyond medicines continue to challenge patients. In September 2026, Karnataka's Health Minister highlighted markups ranging from 10 to over 52 times the actual procurement cost for various medicines.
Karnataka is experiencing a rising cancer burden, with incidence increasing by 10.2% from 2021 to 2025. This financial strain, termed 'financial toxicity,' forces patients to discontinue or delay treatment, undermining its effectiveness. Doctors emphasize that affordability must extend to advanced therapies like immunotherapy.
While the price intervention is a step, ensuring savings reach patients and maintaining adequate supplies are crucial. Broader measures, including stronger public procurement and transparency in private healthcare billing, are needed to make cancer care truly accessible.
